- Home
- TGTX vs GH Comparison
TGTX vs GH Comparison
Compare TGTX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- GH
- Stock Information
- Founded
- TGTX 1993
- GH 2011
- Country
- TGTX United States
- GH United States
- Employees
- TGTX N/A
- GH N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- GH Medical Specialities
- Sector
- TGTX Health Care
- GH Health Care
- Exchange
- TGTX Nasdaq
- GH Nasdaq
- Market Cap
- TGTX 4.2B
- GH 4.9B
- IPO Year
- TGTX 1995
- GH 2018
- Fundamental
- Price
- TGTX $33.09
- GH $56.68
- Analyst Decision
- TGTX Strong Buy
- GH Strong Buy
- Analyst Count
- TGTX 4
- GH 17
- Target Price
- TGTX $42.50
- GH $58.24
- AVG Volume (30 Days)
- TGTX 2.0M
- GH 2.3M
- Earning Date
- TGTX 11-03-2025
- GH 11-05-2025
- Dividend Yield
- TGTX N/A
- GH N/A
- EPS Growth
- TGTX N/A
- GH N/A
- EPS
- TGTX 0.36
- GH N/A
- Revenue
- TGTX $454,069,000.00
- GH $828,849,000.00
- Revenue This Year
- TGTX $82.58
- GH $28.07
- Revenue Next Year
- TGTX $44.99
- GH $21.61
- P/E Ratio
- TGTX $88.20
- GH N/A
- Revenue Growth
- TGTX 30.96
- GH 28.74
- 52 Week Low
- TGTX $21.16
- GH $20.14
- 52 Week High
- TGTX $46.48
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- TGTX 54.72
- GH 47.38
- Support Level
- TGTX $31.34
- GH $53.40
- Resistance Level
- TGTX $32.56
- GH $61.95
- Average True Range (ATR)
- TGTX 1.03
- GH 2.39
- MACD
- TGTX -1.33
- GH -1.27
- Stochastic Oscillator
- TGTX 99.06
- GH 22.47
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.